Adverse events occurring in at least 3% of patients after 4 cycles of PCD (n = 100)
. | Grade 1 to 2, n (%) . | Grade 3 to 4, n (%) . |
---|---|---|
Adverse event | 97 (97%) | 73 (73%) |
Blood and lymphatic system disorders | 25 (25%) | 100 (100%) |
Anemia | 9 (9%) | 7 (7%) |
Neutropenia | 8 (8%) | 51 (51%) |
Lymphopenia | 4 (4%) | 37 (37%) |
Thrombocytopenia | 4 (4%) | 5 (5%) |
Gastrointestinal disorders | 71 (71%) | 2 (2%) |
Constipation | 23 (23%) | 1 (1%) |
Diarrhea | 16 (16%) | 0 (0%) |
Nausea | 12 (12%) | 0 (0%) |
Abdominal pain (upper) | 11 (11%) | 1 (1%) |
Vomiting | 5 (5%) | 0 (0%) |
Hemorrhoids | 4 (4%) | 0 (0%) |
Constitutional | 65 (65%) | 3 (3%) |
Asthenia | 50 (50%) | 3 (3%) |
Edema (peripheral) | 15 (15%) | 0 (0%) |
Immune system disorders | 8 (8%) | 3 (3%) |
Hypersensitivity | 8 (8%) | 3 (3%) |
Infections | 49 (49%) | 6 (6%) |
Bronchitis | 25 (25%) | 0 (0%) |
Nasopharyngitis | 9 (9%) | 0 (0%) |
Gastroenteritis | 8 (8%) | 0 (0%) |
Sinusitis | 4 (4%) | 0 (0%) |
Pneumonia | 3 (3%) | 6 (6%) |
Metabolism | 7 (7%) | 4 (3%) |
Hyperglycemia | 4 (4%) | 4 (3%) |
Hypokalemia | 3 (3%) | 0 (0%) |
Musculoskeletal | 51 (51%) | 2 (2%) |
Muscle spasms | 22 (22%) | 0 (0%) |
Bone pain | 20 (20%) | 2 (2%) |
Muscular weakness | 5 (5%) | 0 (0%) |
Myalgia | 4 (4%) | 0 (0%) |
Nervous system disorders | 25 (25%) | 0 (0%) |
Tremor | 14 (14%) | 0 (0%) |
Peripheral sensory neuropathy | 7 (7%) | 0 (0%) |
Dysesthesia | 4 (4%) | 0 (0%) |
Psychiatric disorders | 47 (47%) | 1 (1%) |
Insomnia | 22 (22%) | 1 (1%) |
Irritability | 7 (7%) | 0 (0%) |
Sleep disorder | 6 (6%) | 0 (0%) |
Agitation | 4 (4%) | 0 (0%) |
Anxiety | 4 (4%) | 0 (0%) |
Depression | 4 (4%) | 0 (0%) |
Respiratory, thoracic and mediastinal disorders | 39 (39%) | 3 (3%) |
Dyspnea | 15 (15%) | 2 (2%) |
Cough | 11 (11%) | 1 (1%) |
Dysphonia | 5 (5%) | 0 (0%) |
Dyspnea exertional | 4 (4%) | 0 (0%) |
Hiccups | 4 (4%) | 0 (0%) |
Skin disorders | 25 (25%) | 1 (1%) |
Rash | 10 (10%) | 1 (1%) |
Erythema | 9 (9%) | 0 (0%) |
Hyperhidrosis | 6 (6%) | 0 (0%) |
Vascular disorders | 5 (5%) | 0 (0%) |
Flushing | 5 (5%) | 0 (0%) |
. | Grade 1 to 2, n (%) . | Grade 3 to 4, n (%) . |
---|---|---|
Adverse event | 97 (97%) | 73 (73%) |
Blood and lymphatic system disorders | 25 (25%) | 100 (100%) |
Anemia | 9 (9%) | 7 (7%) |
Neutropenia | 8 (8%) | 51 (51%) |
Lymphopenia | 4 (4%) | 37 (37%) |
Thrombocytopenia | 4 (4%) | 5 (5%) |
Gastrointestinal disorders | 71 (71%) | 2 (2%) |
Constipation | 23 (23%) | 1 (1%) |
Diarrhea | 16 (16%) | 0 (0%) |
Nausea | 12 (12%) | 0 (0%) |
Abdominal pain (upper) | 11 (11%) | 1 (1%) |
Vomiting | 5 (5%) | 0 (0%) |
Hemorrhoids | 4 (4%) | 0 (0%) |
Constitutional | 65 (65%) | 3 (3%) |
Asthenia | 50 (50%) | 3 (3%) |
Edema (peripheral) | 15 (15%) | 0 (0%) |
Immune system disorders | 8 (8%) | 3 (3%) |
Hypersensitivity | 8 (8%) | 3 (3%) |
Infections | 49 (49%) | 6 (6%) |
Bronchitis | 25 (25%) | 0 (0%) |
Nasopharyngitis | 9 (9%) | 0 (0%) |
Gastroenteritis | 8 (8%) | 0 (0%) |
Sinusitis | 4 (4%) | 0 (0%) |
Pneumonia | 3 (3%) | 6 (6%) |
Metabolism | 7 (7%) | 4 (3%) |
Hyperglycemia | 4 (4%) | 4 (3%) |
Hypokalemia | 3 (3%) | 0 (0%) |
Musculoskeletal | 51 (51%) | 2 (2%) |
Muscle spasms | 22 (22%) | 0 (0%) |
Bone pain | 20 (20%) | 2 (2%) |
Muscular weakness | 5 (5%) | 0 (0%) |
Myalgia | 4 (4%) | 0 (0%) |
Nervous system disorders | 25 (25%) | 0 (0%) |
Tremor | 14 (14%) | 0 (0%) |
Peripheral sensory neuropathy | 7 (7%) | 0 (0%) |
Dysesthesia | 4 (4%) | 0 (0%) |
Psychiatric disorders | 47 (47%) | 1 (1%) |
Insomnia | 22 (22%) | 1 (1%) |
Irritability | 7 (7%) | 0 (0%) |
Sleep disorder | 6 (6%) | 0 (0%) |
Agitation | 4 (4%) | 0 (0%) |
Anxiety | 4 (4%) | 0 (0%) |
Depression | 4 (4%) | 0 (0%) |
Respiratory, thoracic and mediastinal disorders | 39 (39%) | 3 (3%) |
Dyspnea | 15 (15%) | 2 (2%) |
Cough | 11 (11%) | 1 (1%) |
Dysphonia | 5 (5%) | 0 (0%) |
Dyspnea exertional | 4 (4%) | 0 (0%) |
Hiccups | 4 (4%) | 0 (0%) |
Skin disorders | 25 (25%) | 1 (1%) |
Rash | 10 (10%) | 1 (1%) |
Erythema | 9 (9%) | 0 (0%) |
Hyperhidrosis | 6 (6%) | 0 (0%) |
Vascular disorders | 5 (5%) | 0 (0%) |
Flushing | 5 (5%) | 0 (0%) |